<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01021241</url>
  </required_header>
  <id_info>
    <org_study_id>ENZ-101</org_study_id>
    <nct_id>NCT01021241</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Intravenous Uricase-PEG 20</brief_title>
  <official_title>A Cohort Dose-Escalation Phase 1 Study of Intravenous Infusion of Uricase-PEG 20</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EnzymeRx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EnzymeRx</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, pharmacokinetics and pharmacodynamics of
      single intravenous doses of Uricase-PEG 20.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Uricase is an enzyme (found in most mammals but not humans) that converts poorly soluble uric
      acid into highly soluble allantoin. Because humans lack uricase, they are prone to develop
      elevated levels of uric acid, which can form crystals in the joints and soft tissues. In
      those which chronically elevated uric acid, gout may develop. In the setting of acute rises
      in uric acid, seen for example in tumor lysis syndrome, uric acid crystals can damage the
      renal tubules. Uricase-PEG 20 is a recombinant uricase conjugated with multiple PEG molecules
      designed to prolong the half-life and decrease the immunogenicity of uricase. This study will
      characterize the safety, pharmacokinetics and pharmacodynamics of intravenous Uricase-PEG 20,
      the anticipated route of administration to be used in future clinical development in tumor
      lysis syndrome.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2009</start_date>
  <completion_date type="Anticipated">March 2010</completion_date>
  <primary_completion_date type="Anticipated">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety (assessment of signs and symptoms and clinical laboratory measurements following administration of Uricase-PEG 20, graded according to the Common Toxicity Criteria for Rheumatology, version 2.0)</measure>
    <time_frame>Through Day 35 after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (Uricase-PEG 20 serum concentration)</measure>
    <time_frame>Through Day 35 after dosing</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics (plasma uric acid concentration)</measure>
    <time_frame>Through Day 35 after dosing</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Gout</condition>
  <condition>Hyperuricemia</condition>
  <arm_group>
    <arm_group_label>Uricase-PEG 20</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cohorts will receive ascending doses of Uricase-PEG 20 in a sequential manner</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Uricase-PEG 20</intervention_name>
    <description>Intravenous infusion of Uricase-PEG 20 over one hour; no premedication</description>
    <arm_group_label>Uricase-PEG 20</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Serum uric acid &gt; 6 mg/dL (men) or &gt; 5 mg/dL (women)

          -  Clinical laboratory values within normal limits or not clinically significant

          -  Women should be menopausal or peri-menopausal

        Exclusion Criteria:

          -  Prior exposure to uricase

          -  History of severe allergic reactions, or any allergy to PEG or pegylated products

          -  G6PD or catalase deficiency

          -  Medical condition that may interfere with ability to complete the study (e.g.,
             uncontrolled diabetes or hypertension, congestive heart failure NYHA Class III or IV,
             history of myocardial infarction, immunosuppression, pregnancy)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony S Fiorino, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>EnzymeRx, LLC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alan Kivitz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Altoona Center for Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MRA Clinical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.enzymerx.com</url>
    <description>Homepage of sponsoring company</description>
  </link>
  <link>
    <url>http://ash.confex.com/ash/2009/webprogram/Paper21744.html</url>
    <description>Abstract describing animal pharmacokinetic studies</description>
  </link>
  <reference>
    <citation>Bomalaski JS, Holtsberg FW, Ensor CM, Clark MA. Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies. J Rheumatol. 2002 Sep;29(9):1942-9.</citation>
    <PMID>12233890</PMID>
  </reference>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 24, 2009</study_first_submitted>
  <study_first_submitted_qc>November 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2009</study_first_posted>
  <last_update_submitted>February 22, 2010</last_update_submitted>
  <last_update_submitted_qc>February 22, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 23, 2010</last_update_posted>
  <responsible_party>
    <name_title>Anthony Fiorino, MD, PhD</name_title>
    <organization>EnzymeRx, LLC</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rasburicase</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

